Overview
Syllabus
Intro
Disclosures
Three Inherited Risk Measures
Genetic Risk Score
Does GRS Work?
Broad-sense Validity
Narrow-sense Validity
Current Clinical Practice
Hypothesis for the Need
Direct Evidence from UKB
GRS of PCa in UKB
RPMs of PCa in UKB
Association with PCa Risk/Mortality
Simple and Clean Analysis
PCa Diagnosis-free Survival
Benefits of Genetic Assessment in
Predicting Risk: PCa Screening
Rare Pathogenic Mutations (RPMs)
Consistent Evidence for HOXB13
Evidence for Prostate Cancer Susceptibility Genes
Cumulative Effects of 100 SNPs
GRS Modifies BRCA2 Effect in PCa
Predicting Prognosis: Early Stage
Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate cancer and are Associated with Early Age at Death
Predicting Therapeutic Responses: Late Stage
BRCA2 mutations and Response to Carboplatin-based Therapy
High Levels of Microsatellite instability (MSI-H) and DNA Mismatch Repair Gene (MMR) Mutations: Actionable with Anti-PD-L1 agents
Conclusions
Case Example
Management?
Surgical Specimen
Taught by
Ambry Genetics